Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
10 Sep 2017 ESMO 2017 Press Release: Combination Immunotherapy in Second/third Line Extends Mesothelioma Survival to 15 Months Lung and other thoracic tumours
10 Sep 2017 ESMO 2017 Press Release: Abemaciclib Initial Therapy Improves Outcome in Endocrine-sensitive Advanced Breast Cancer Breast cancer
10 Sep 2017 ESMO 2017 Press Release: Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Mature Results Favour Pembrolizumab As Second-line Treatment For Bladder Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Study Shows ESMO Magnitude of Benefit Scale Can Be Used to Grade Orphan Drugs
10 Sep 2017 ESMO 2017 Press Release: Study Confirms Chemoradiation is Best Treatment for Locally Advanced Cervical Cancer Gynaecologic malignancies
10 Sep 2017 ESMO 2017 Press Release: Cancer Patients Struggle with Key Aspects of Clinical Trial Methodology
09 Sep 2017 ESMO 2017: Front-Line Osimertinib Poised to Become Standard of Care in EGFR-Mutation Positive NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
09 Sep 2017 ESMO 2017: Durvalumab as Consolidation Therapy Prolongs PFS in Stage III NSCLC Patients Without Progression Following Platinum-based Chemoradiotherapy Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
09 Sep 2017 ESMO 2017: Large Dataset of Targetable Genomic Alterations Created Using Liquid Biopsy Translational research
09 Sep 2017 ESMO 2017: Subtypes of Thymic Carcinomas Show Different Genomic Alterations and Tumour Mutational Burden Endocrine and neuroendocrine tumours - Translational research
09 Sep 2017 ESMO 2017: Tumour Subtype Specific Genetic Alterations Detected by Comprehensive Genomic Profiling Translational research
09 Sep 2017 ESMO 2017: Sub-study of the GAND-Emesis Trial with Neurokinin-1 Receptor Antagonist During Concomitant Chemoradiotherapy for Cervical Cancer Palliative and supportive care
09 Sep 2017 ESMO 2017: Clinical Trial Toxicity Reporting by Investigators May Not Reflect Patients’ Viewpoint Palliative and supportive care
09 Sep 2017 ESMO 2017: Adjuvant Imatinib Recommended Only for Patients with High-risk GIST Sarcomas - Anticancer agents & Biologic therapy